Navigation

torsemide (Demadex)

 

Classes: Diuretics, Loop

Dosing and uses of Demadex (torsemide)

 

Adult dosage forms and strengths

tablet

  • 5mg
  • 10mg
  • 20mg
  • 100mg

injectable solution

  • 10mg/mL

 

Congestive Heart Failure

10-20 mg PO/IV once daily initially; doubled until desired diuretic effect is achieved; individual dose not to exceed 200 mg

 

Chronic Renal Failure

20 mg PO/IV once daily initially; doubled until desired diuretic effect is achieved; individual dose not to exceed 200 mg

 

Hepatic Cirrhosis

5-10 mg PO/IV once daily initially with aldosterone antagonist or potassium-sparing diuretic; individual dose not to exceed 40 mg

 

Hypertension

2.5-5 mg/day PO initially; increased to 10 mg/day PO in 4-6 weeks PRn

 

Dosing Considerations

Use for fluid retention refractory to thiazides or with impaired renal function

Overdose management

  • Normal saline may be used for volume replacement
  • Dopamine or norepinephrine may be used to treat hypotension
  • If dysrhythmia due to decreased potassium or magnesium is suspected, replace aggressively
  • Discontinue treatment if no symptoms are apparent after 6 hours

 

Pediatric dosage forms and strengths

Safety and efficacy not established

 

Demadex (torsemide) adverse (side) effects

1-10%

Excessive urination (7%)

Headache (7%)

Electrolyte imbalance (2-4%)

Dizziness (3%)

Rhinitis (3%)

Constipation (2%)

Cough (2%)

Diarrhea (2%)

Dyspepsia (2%)

Nausea (2%)

Insomnia (1%)

Nervousness (1%)

 

<1%

Fatigue

Hyperuricemia

Low back pain

Muscle cramps

Orthostatic hypotension

Ototoxicity (tinnitus and hearing loss, usually reversible; avoid doses >200 mg)

Pruritus

Rash

 

Postmarketing Reports

Leukopenia

Pancreatitis

Serious skin reactions (ie, Stevens-Johnson syndrome, toxic epidermal necrolysis)

Thrombocytopenia

 

Warnings

Contraindications

Documented hypersensitivity to torsemide or sulfonamides

Anuria

 

Cautions

Use with caution in diabetes mellitus, fluid or electrolyte imbalance (hypokalemia, hyponatremia), hyperglycemia, hyperlipidemia, hyperuricemia or gout, severe liver disease with cirrhosis and ascites

Risk of ototoxicity (occurring after rapid IV injection)

Use with caution in cirrhosis; avoid changes in fluid and electrolyte balance and acid-base status, which may lead to hepatic encephalopathy

Monitor fluid status and renal function to prevent azotemia, oliguria, and reversible increases in blood urea nitrogen (BUN) and creatinine

 

Pregnancy and lactation

Pregnancy category: B

Lactation: Unknown whether drug is excreted into breast milk; use with caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Demadex (torsemide)

Mechanism of action

Sulfonylurea diuretic; loop diuretic acting at Na-K-2Cl reabsorptive pump at ascending loop of Henle; interferes with chloride-binding cotransport system, causing increased excretion of water, sodium, chlorine, magnesium, and calcium

 

Absorption

Bioavailability: 80%

Onset: PO, 1 hr

Duration: PO, 6-8 hr; IV, 6 hr

Peak plasma time: PO, 1 hr

Peak effect: Diuresis, 1-2 hr; antihypertensive effect, 4-6 wk

 

Distribution

Protein bound: 99%

Vd: 12-15 L (doubled in cirrhosis)

 

Metabolism

Metabolized in liver by CYP450 system

Metabolites: M1 (active), M3 (active), M5 (inactive)

 

Elimination

Half-life: 3.5 hr

Dialyzable: Hemodialysis, no

Renal clearance: 0.38-0.78 L/hr

Excretion: Urine (20%)

 

Administration

IV Compatibilities

Solution: D5W

Y-site: Milrinone

 

IV Administration

Administer either as slow injection over 2 minutes or as continuous infusion

If given through IV line, flushing with NS before and afterward is recommended

 

Storage

Store at controlled room temperature

Protect from freezing